News | May 28, 2013

Clinical Data Shows Positive Results for CardioKinetix Device to Treat Heart Failure

Meta-analysis substantiates potential of breakthrough treatment for heart failure patients — largest group studied to date

May 28, 2013 — CardioKinetix Inc. has announced the results of a meta-analysis study of the catheter-based Parachute Ventricular Partitioning Device. Six-month clinical results from 91 U.S. and European patients with ischemic heart failure were presented.

“The results of this meta-analysis, which represents the largest group of patients studied to date, are consistent with previous positive findings and continue to substantiate the Parachute treatment as a viable technology,” said Martyn Thomas, M.D., chairman of Cardiology at St. Thomas Hospital in London, England. “The Parachute promises to revolutionize the treatment for heart attack survivors whose hearts enlarge over time and subsequently suffer from heart failure symptoms, offering hope for a better qualify of life for many patients.”

Clinical data from 91 patients to reach six-month followup demonstrates successful delivery and deployment of the Parachute implant, without the occurrence of major adverse cardiac events (MACE) related to the device, in 90 percent (82/91) of patients at six months following treatment. In addition, six months following treatment, 89 percent of patients demonstrated improved or maintained New York Heart Association (NYHA) functional class status. Specifically in the NYHA III subgroup, 27 percent improved two classes. The treatment also demonstrated a reduction in left ventricular volume, with a 20 percent reduction in end diastolic volume.

After a heart attack, many patients experience enlargement of their left ventricle causing a decrease in cardiac output resulting in heart failure symptoms such as shortness of breath. Treatment options for patients whose ventricle has enlarged are limited. The Parachute device offers the first minimally invasive catheter-based treatment to partition the damaged muscle, excluding the non-functional heart segment from the healthy, functional segment to decrease the overall volume of the left ventricle and restore its geometry and function.

For more information: www.cardiokinetix.com

Related Content

Videos | Structural Heart | September 14, 2018
A discussion with William O’Neill, M.D., director of the Henry Ford...
A MitraClip device being deployed to clasp together the leaflets of the mitral valve. This mimics a surgical suture repair to create a double orifice valve with better leaflet coaptation to prevent mitral regurgitation. Abbott Mitraclip device.

A MitraClip device being deployed to clasp together the leaflets of the mitral valve. This mimics a surgical suture repair to create a double orifice valve with better leaflet coaptation to prevent mitral regurgitation.

News | Structural Heart | May 11, 2018
May 11, 2018 — The post-approval study evaluating the safety and efficacy of MitraClip in a real-world, commercial se
SAVR, surgical aortic valve replacement, elderly patients, aortic stenosis, Society of Thoracic Surgeons, clinical study
News | Structural Heart | January 25, 2017
Elderly patients with aortic stenosis (AS) and medium surgical risk experienced better than expected results after...
Videos | Structural Heart | November 09, 2016
Brijeshwar Maini, M.D., and Brian Bethea, M.D., from Tenet Florida’s structural heart program, explain the importance
aortic dissection, family history, same age, clinical study, John A. Elefteriades, Annals of Thoracic Surgery
News | Structural Heart | August 25, 2016
People with a family member who had an aortic dissection — a spontaneous tear in one of the body’s main arteries —...
Videos | Structural Heart | June 30, 2016
Interview with Stephen Little, M.D., medical director of the Valve Clinic at the Houston Methodist DeBakey Heart and
AATS 2016, tricuspid regurgitation, post mitral valve repair, Tirone E. David, atrial fibrillation
News | Structural Heart | May 16, 2016
At the 96th American Association for Thoracic Surgery (AATS) Annual Meeting, investigators presented the results of a...
CABG, mitral valve repair, ischemic mitral regurgitation, IMR, study, ACC 2016
News | Structural Heart | April 11, 2016
Just-released two-year follow-up data comparing coronary-artery bypass grafting (CABG) with combined CABG and mitral-...
V-Wave Interarterial Shunt, first human results, The Lancet, heart failure, HF
News | Structural Heart | March 28, 2016
V-Wave Ltd, maker of an investigational interatrial shunt device for patients with advanced heart failure (HF),...
News | Structural Heart | March 02, 2016
Edwards Lifesciences Corp. announced U.S. Food and Drug Administration (FDA) approval to expand use of the Edwards...
Overlay Init